In Brief: 3M Pharmaceuticals
This article was originally published in The Gray Sheet
3M Pharmaceuticals: Receives FDA marketing approval for Proventil HFA, "the first chlorofluorocarbon-free metered dose inhaler" in the U.S. Proventil uses hydrofluoroalkane-134a, which has been approved by the Environmental Protection Agency as a replacement for ozone-damaging chlorofluorocarbons, as a propellant for the asthma medication albuterol sulfate, the St. Paul Minnesota firm explains. 3M will manufacture Proventil; Schering-Plough is the exclusive U.S. distributor...
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.